Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer by shutting down one of cancer's most commonly mutated pathways.
San Diego, CA
Joined July 2021
- Tweets16
- Following12
- Followers161
- Likes1
Erasca has won the @BioTech_Awards 2026 R&D Platform of the Year award! Thank you to our team, researchers, clinicians, patients and partners for helping advance our mission to erase cancer
Learn more about our work: bit.ly/4BF5oii
ALT Two individuals in lab coats and safety glasses are working side by side. A banner to the left reads "Erasca Winner" with the text "R&D Platform of the Year, 2026 Biotech Breakthrough Awards.
1
56
This November, Erasca’s management team will attend @GuggenheimSec, @Stifel, and @Jefferies #healthcare conferences to meet with investors and share progress in advancing therapies for RAS/MAPK-driven #cancers.
More here: bit.ly/4A9A6OT
November is #LungCancerAwarenessMonth and #PancreaticCancerAwarenessMonth. We’re advancing new therapies for RAS/MAPK-driven cancers, including lung and pancreatic cancers, toward our mission of erasing cancer. Learn more: bit.ly/4BF5oii
48
Little Erascals, BIG Halloween spirit! 🎃 Our team and their families celebrated with costumes, trick-or-treating, snacks, and crafts. Here’s a peek at the fun! #TeamErasca #HappyHalloween
1
2
109
Thank you, @LustgartenFDN, for the Hope Through Science Award. We’re proud to support the shared mission of improving outcomes for patients with pancreatic cancer. #PancreaticCancer
RAS mutations drive ~30% of all cancers. Thank you, @stephaniesirota, for the opportunity to discuss Erasca’s journey and our commitment to advancing therapies for patients with RAS/MAPK-driven cancers. #ASCO2026
In our #ASCO2026 coffee break miniseries, RTW CBO @stephaniesirota chatted with Dr. Shannon Morris, Chief Medical Officer of @Erasca. Dr. Morris shared the story behind Erasca's name and what it took to pursue a corner of oncology that was historically considered undruggable. The mic drop moment is when Dr. Morris shares that RAS mutations drive 30% of all tumor types.
219
Please join us for this exciting event!
Please join us on Tuesday, April 12th at 4:30 PM EDT for the @Erasca Investor Event featuring Scott Kopetz, M.D., Ph.D., (MD Anderson Cancer Center). A live Q&A session will follow. Register here: lifesci.events/ERAS
